Mar 10, 2022 | Press Releases
M-Life’s™ Molecular Systems Approach is Proving Itself as the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful advancement of its anti-cancer prospect MLS-222QLD in preclinical testing. This molecule is one of several...
Dec 18, 2021 | Press Releases
SAN DIEGO, CALIFORNIA, DECEMBER, 2021 – iCFO Capital recently partnered with Moskal Lifesciences, LLC to raise $3.5M seed funding for expand growth from iCFO Capital investor network in San Diego, California. Moskal Lifesciences, LLC uses Novel Algorithms to Identify...
Nov 20, 2020 | Press Releases
M-Life’s™ Molecular Systems Approach Enables Understanding of Efficacy and Toxicity Origins at the Atomic Level Leading to the Next Generation for Drug Discovery NASHVILLE, TENNESSEE – M-LIFE™ announced the successful conclusion of IL-6 molecular systems milestone...
Oct 9, 2020 | Press Releases
NASHVILLE, TENNESSEE – M-LIFE™ has identified 8 drugs as prospective repurposing targets to address the cytokine storm associated with severe COVID-19 cases. As with M-Life’s™ prior list of repurposing targets directed at the virus, prospective cytokine candidates...
Sep 11, 2020 | Press Releases
NASHVILLE, TENNESSEE – M-LIFE™ has predicted the toxicity profiles across multiple organ systems for a variety of prospective re-purposed COVID-19 drugs. The objective for identifying prospective repurposed drugs is to find on-market therapeutics having the potential...
Aug 8, 2020 | Press Releases
M-LIFE™, a biotech and life sciences company, has identified six marketed drugs suitable for repurposing as possible therapies for COVID-19. These drugs have not been previously indicated via the mainstream media. Additionally, these newly identified prospects...
